TAK
Takeda Pharmaceutical Company (TAK)
Healthcare • NYSE • $18.18+0.28%
- Symbol
- TAK
- Exchange
- NYSE
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Price
- $18.18
- Daily Change
- +0.28%
- Market Cap
- $56.30B
- Trailing P/E
- N/A
- Forward P/E
- 33.26
- 52W High
- $18.90
- 52W Low
- $12.99
- Analyst Target
- $22.00
- Dividend Yield
- +3.50%
- Beta
- 0.10
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, oncology, vaccines, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Takhzyro, Advate, Elaprase, Replagal, Vpriv, Adynovate/Adynovi, Livtencity, ADZYNMA, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Flexbumin, Adcetris, Leuplin/Enantone, Ninlaro, Iclusig, FRUZAQLA, Alunbrig, vyvanse/elvanse, Trintellix, and QDENGA brands. It has licensing and collaboration for the development and commercialization of products with Arrowhead Pharmaceuticals, Cour Pharmaceuticals, Engitix, Halozy…
Company websiteResearch TAK on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.